ஆஞ்சியோலஜி: திறந்த அணுகல்
திறந்த அணுகல்

சுருக்கம்

Randomized Controlled Trials of Ginkgo Ketone Ester Dropping Pills as Adjuvant Therapy for Coronary Heart Disease Angina: A Systematic Review and Meta-Analysis

Xiao-Min Xue, Ying-Zhi Chen, Shi-Yong Chen, Yu Li, Jie Wang, Hui-Fang Zhou, Si-Si Chen, Ren Zhao Wu

Objective: Coronary Heart Disease (CHD) is one of the most common cardiovascular diseases in clinic. Ginkgo biloba Ketone Ester Dripping Pill (GKEDP) is a kind of Chinese patent medicine mainly developed by Ginkgo biloba ketone ester, widely used in treating cardiovascular diseases. This study aimed to evaluate the efficacy and safety of GKEDP combined with conventional drug therapy in the treatment of Coronary Heart Disease Angina (CHDA).

Methods: Chinese and foreign literature databases were searched by computer, and all the clinical research literature of GKEDP combined with Conventional drug therapy in treating CHDA were collected. The publication time was from the establishment of the database to September 1, 2020, without language restriction, and the type of literature was limited to Randomized Controlled Trials (RCTs). According to the inclusion and exclusion criteria, two researchers independently screened the literature and evaluated the included research quality. They would decide after discussion if any divergence. Finally, the relevant original data were extracted from the incorporated literature and statistically analyzed by Revman 5.3.

Results: Ten RCT literature was finally collected with a total sample size of 1065 cases, including 533 cases in the experimental and 532 cases in the control group. Meta-analysis showed that GKEDP combined with conventional drug therapy could significantly improve the effective rate of treatment on angina pectoris [RR=1.21, 95%CI (1.15, 1.28), p<0.00001] and reduce times of angina attack [MD=-6.17, 95%CI (8.19) p<0.01], duration of angina attack [MD=-2.38, 95%CI (-3.27, -1.49), p<0.01] and chest tightness times [MD=-1.25, 95%CI (-1.92, -0.57), p<0.01] substantially.

Conclusion: GKEDP as adjuvant therapy for CHDA can significantly improve the effective rate of treatment, reduce times of angina attacks, duration of angina attacks, and chest tightness times, indicating that it can enhance the curative effect, improve symptoms and quality of life. The quality of research included in this study was low and the sample was small. Other RCTs with strict design, long treatment course, and large samples were needed to confirm these results.